Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acetazolamide sodium
Drug ID BADD_D00026
Description One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Indications and Usage For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma
Marketing Status approved; vet_approved
ATC Code S01EC01
DrugBank ID DB00819
KEGG ID D01196
MeSH ID D000086
PubChem ID 13290219
TTD Drug ID D0E1SW
NDC Product Code 67457-853; 63552-116
UNII 429ZT169UH
Synonyms Acetazolamide | Acetazolam | Acetazolamide Sodium, (Sterile) | Acetazolamide, Monosodium Salt | Ak-Zol | Ak Zol | AkZol | Apo-Acetazolamide | Apo Acetazolamide | ApoAcetazolamide | Diacarb | Diamox | Diuramide | Défiltran | Edemox | Glauconox | Glaupax | Huma-Zolamide | Huma Zolamide | HumaZolamide | Acetadiazol
Chemical Information
Molecular Formula C4H5N4NaO3S2
CAS Registry Number 1424-27-7
SMILES CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agranulocytosis01.02.03.001---
Aplastic anaemia01.03.03.002---
Confusional state17.02.03.005; 19.13.01.001--
Diarrhoea07.02.01.001--
Dysgeusia07.14.03.001; 17.02.07.003--
Electrolyte imbalance14.05.01.002---
Gastrointestinal disorder07.11.01.001---
Glycosuria20.02.01.005--
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Hepatic failure09.01.03.002--
Hepatic necrosis09.01.07.002--
Melaena07.12.02.004; 24.07.02.013---
Metabolic acidosis14.01.01.003---
Myopia06.02.04.002---
Nausea07.01.07.001--
Paraesthesia17.02.06.005; 23.03.03.094--
Paralysis17.01.04.004---
Photosensitivity reaction23.03.09.003--
Polyuria20.02.03.002---
Seizure17.12.03.001--
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Urticaria10.01.06.001; 23.04.02.001--
Vomiting07.01.07.003--
Hypoacusis04.02.01.006--
Decreased appetite08.01.09.028; 14.03.01.005--
Blood disorder01.05.01.004---
The 1th Page    1    Total 1 Pages